Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

FDA Places Clinical Hold on Phase 1 Trial of XMT-2056 in HER2-expressing Solid Tumors

March 13th 2023

The FDA has placed a clinical hold on a phase 1 trial investigating the antibody-drug conjugate XMT-2056 for the treatment of patients with advanced/recurrent solid tumors that express HER2.

Future Directions in Precision Medicine: An Evolving Treatment Landscape

March 13th 2023

Closing out their discussion on biomarkers and precision medicine in cancer care, key opinion leaders look toward future evolutions in the oncology landscape.

Role of a Pharmacist in Developing Treatment Pathways and Educating Patients

March 13th 2023

Ryan Haumschild, PharmD, MS, MBA, reflects on how oncologic pharmacists can help to develop treatment pathways and educate patients on precision medicine.

ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC

March 11th 2023

Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.

Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making

March 10th 2023

Precision medicine has arrived in all stages of prostate cancer care and recommendations for optimal testing and how best to leverage the results to inform clinical decisions continue to rapidly evolve.

Response-Guided Therapy Is the Next Frontier for Tailoring Therapy in HER2+ Breast Cancer

March 10th 2023

Lisa M. Carey, MD, ScM, FASCO, discusses upcoming treatments that could impact standard-of-care practices and the continually evolving role of antibody-drug conjugates role in the breast cancer treatment paradigm.

Increased Germline Testing Rates Promote Crucial Breast Cancer Care

March 8th 2023

Susan M. Domchek, MD, highlights key points related to her presentation on germline testing and breast cancer treatment.

BET Inhibitors in Cancer Therapy: Finding the Right Combination

March 8th 2023

An understanding of BET protein dysregulation, which leads to abnormal expression of oncogenes, has prompted investigators to explore the idea of these proteins as a therapeutic target for cancer.

Updated MAGNITUDE Data Support Niraparib Combination in mCRPC and HRR Gene Alterations

March 8th 2023

Eleni Efstathiou, MD, PhD, expands on the updated interim data from the MAGNITUDE trial and sheds light on the utility of PARP inhibitor combinatorial strategies in patients with mCRPC and HRR gene alterations.

FDA Expands Approval for Companion Diagnostic for Cemiplimab in NSCLC

March 7th 2023

The FDA has approved the VENTANA PD-L1 assay for expanded use in patients with advanced non–small cell lung cancer to help identify patients who may be candidates for treatment with cemiplimab.

Lasofoxifene May Improve Vaginal/Vulvar Symptoms in Postmenopausal ER+/HER2–, ESR1-Mutated Breast Cancer

March 6th 2023

Lasofoxifene improved vaginal/vulvar symptoms compared with fulvestrant in premenopausal patients with locally advanced or metastatic estrogen receptor–positive/HER2-negative breast cancer harboring an ESR1 mutation.

Trastuzumab Deruxtecan Meets ORR End Point in HER2-expressing Advanced Solid Tumors

March 6th 2023

The antibody-drug conjugate trastuzumab deruxtecan met the prespecified target for objective response rate and demonstrated durable responses in heavily pretreated patients with HER2-expressing advanced solid tumors in the phase 2 DESTINY-PanTumor02 trial.

Role of a Pharmacist in the Multidisciplinary Approach to Identifying Biomarkers

March 6th 2023

Expert perspectives on the role of an oncologic pharmacist within a tumor board and how they can improve upon precision medicine in cancer management.

The Value of Molecular Tumor Boards and Multidisciplinary Care

March 6th 2023

Comprehensive discussion on the role of tumor boards—or more specifically, molecular tumor boards—in the optimal management of patients with cancer.

Dr. Sanjana on the Use of Whole-Exome Sequencing to Predict Immunotherapy Response in Advanced Tumors

February 27th 2023

Neville E. Sanjana, PhD, discusses a study on the predictive utility of the Cancer Immunotherapy Response CLassifiEr in advanced-stage cancers.

Improving Uptake of Biomarker Testing and Precision Medicine in Cancer Care

February 27th 2023

Key opinion leaders in the field of cancer management discuss resistance to the uptake of biomarker testing and precision medicine, with deference to the community setting.

Optimizing the Timing and Utilization of Biomarker Testing in Cancer Care

February 27th 2023

Expert pathologist Samuel K. Caughron, MD, FCAP, shares best strategies for the timing and utilization of biomarker testing while managing patients with cancer.

Liquid Biopsies and NGS Stand to Revolutionize Hematologic Malignancies

February 24th 2023

Andrew Ip, MD, delivers a keynote on the role for liquid biopsy and NGS in hematologic malignancies, including the barriers to implementing seamlessly into clinical practice.

Erdafitinib Data in FGFR+ Cholangiocarcinoma Indicates Utility of NGS in Treatment Selection

February 20th 2023

Shubham Pant, MD, MBBS, discusses significant efficacy and safety data from the RAGNAR trial, how erdafitinib fits into the current treatment paradigm for biliary tract cancers, and the role of next-generation sequencing in the selection of FGFR inhibitors for this patient population.

Updating Biomarker Testing Strategies as Cancer Care Evolves

February 20th 2023

Timothy J. Pluard, MD; Ossama Tawfik, MD; and Sujith R. Kalmadi, MD, reflect on how they update their biomarker testing strategies as the field of cancer care and precision medicine evolves.